Core Insights - Tevogen Bio is positioned as a potential leader in the biopharma industry by focusing on cost-efficient, value-driven healthcare solutions amid increasing competition and regulatory changes [1][2] - The company aims to redefine healthcare economics by delivering innovative medical solutions while ensuring affordability and sustainability [3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy biotech company that develops precision T cell therapies targeting infectious diseases and cancers [3] - The company utilizes CD8+ cytotoxic T lymphocytes, which are genetically unmodified, to address significant unmet medical needs [3] - Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and several pending patents related to artificial intelligence [3] Industry Context - The U.S. biotech sector is under pressure to adapt due to the rapid development and lower costs of drugs by Chinese pharmaceutical companies [2] - The appointment of Robert F. Kennedy Jr. as head of the Department of Health and Human Services emphasizes the need for affordable healthcare, prompting discussions on sustainability and access within the industry [2] Leadership and Vision - Tevogen Bio's leadership comprises experienced industry professionals who believe that accessible personalized therapeutics represent the next frontier in medicine [4] - The company is committed to innovative business models that support ongoing medical advancements and patient accessibility [4]

Core Insights - Tevogen Bio is a clinical-stage specialty immunotherapy biotech company focusing on affordable and scalable ExacTcell technology, which has shown positive results in its proof-of-concept clinical trial for TVGN 489 [1][3] - The company aims to address significant unmet needs in treating infectious diseases, cancers, and neurological disorders through precision T cell therapies [3][4] - Tevogen Bio's leadership emphasizes the importance of patient accessibility and innovative business models for sustainability and commercial success in healthcare [3][4] Company Overview - Tevogen Bio utilizes CD8+ cytotoxic T lymphocytes to develop off-the-shelf, genetically unmodified precision T cell therapies [3] - The company has reported positive safety data from its clinical trials and owns key intellectual property assets, including three granted patents and numerous pending patents related to artificial intelligence [3] - The leadership team consists of experienced industry leaders and scientists with expertise in drug development and global product launches [4] Strategic Initiatives - The company discussed ExacTcell's capability to rapidly adapt to emerging viral threats during a meeting with BARDA, positioning it as a potential public health countermeasure [2] - Tevogen Bio plans to follow up with key federal entities and keep stakeholders updated on its progress [2]

Core Insights - Tevogen Bio is advancing its ExacTcell technology, which has shown positive results in clinical trials and is designed to rapidly adapt to emerging viral threats, positioning it as a potential public health countermeasure [1][2]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, genetically unmodified precision T cell therapies targeting infectious diseases, cancers, and neurological disorders [3]. - The company emphasizes the importance of patient accessibility through advanced science and innovative business models to achieve sustainability and commercial success in healthcare [3]. - Tevogen Bio owns key intellectual property assets, including three granted patents and numerous pending patents, with a focus on artificial intelligence [3]. Leadership and Vision - The leadership team at Tevogen Bio consists of experienced industry leaders and distinguished scientists with expertise in drug development and global product launches [4]. - The company believes that accessible personalized therapeutics represent the next frontier in medicine and that disruptive business models are essential for sustaining medical innovation [4].

WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Patton on being appointed Deputy Assistant to the President and Director of Minority Outreach. Ms. Patton will join the Office of Public Liaison and will be responsible for ensuring that President Trump continues to build upon his Election Day support from Blacks, Latinos and W ...

WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Patton on being appointed Deputy Assistant to the President and Director of Minority Outreach. Ms. Patton will join the Office of Public Liaison and will be responsible for ensuring that President Trump continues to build upon his Election Day support from Blacks, Latinos and ...

Core Article Summary - Tevogen Bio Holdings Inc expands its AI-focused collaboration with Microsoft to enhance its PredicTcell technology, leveraging Microsoft's AI, cloud capabilities, and health/life sciences expertise to accelerate target identification and pre-clinical processes [1] - The collaboration aims to strengthen Tevogen Bio's pipeline of innovative immunotherapies for infectious diseases and cancers [1] TevogenAI and Microsoft Integration - TevogenAI integrates Microsoft's advanced AI tools and Azure cloud platform to achieve two key objectives: 1) Rapidly expand the ExacTcell™ Technology Pre-Clinical Pipeline by using machine learning for critical simulations to accelerate new target identification [2] 2) Develop proprietary algorithms to decode HLA-T cell interactions, enhancing understanding of immune responses and opening new therapeutic avenues [3] Strategic Goals and Leadership Perspective - The expanded relationship with Microsoft is seen as a milestone in revolutionizing immunotherapy, with a focus on delivering precise and personalized treatments at an accelerated pace [4] - Tevogen Bio is proactively investigating potential treatments for HPV using its proprietary ExacTcell™ technology, aiming to deliver an HPV-specific CTL treatment [4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, genetically unmodified precision T cell therapies for infectious diseases, cancers, and neurological disorders [5] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and nine pending US patents [5] - Tevogen Bio is led by a team of experienced industry leaders and scientists, emphasizing accessible personalized therapeutics and disruptive business models to sustain medical innovation [6] Additional Notes - The collaboration with Microsoft is part of the previously announced Microsoft for Startups program [7] - PredicTcell, Tevogen Bio's proprietary technology, is designed for predictive, precision T cell target identification [7]

The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.Pioneering the Economics of Health to examine the interdependencies of the healthcare ecosystem which are often overlooked when only considering a singular silo of it.AI In Biopharma to highlight how AI-driven technologies can revolutionize drug discover ...

WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The panel, titled "AI in Biopharma: Next Frontier of Medical Innovation," will explore the transf ...

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, filed for an additional patent, “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models”, as part of its developing intellectual property portfolio. In October 2023, Tevogen Bio launched its ar ...

Full name for licenses is Anthony Joseph ("A.J.") Cataldo II, PhD, CPA. Retired university accounting professor, CMA, CGMA and author of 10 books and 200+ articles and columns in 50+ different journals and outlets, with experience as CFO, Government Auditor, Public Accountant and Litigation Support Expert Witness in cases involving GM, Ford, and other big cap firms. Years ago, the Securities and Exchange Commission used 3 of my research articles in a fraud case. I have taught at 10 universities including No ...